Evidence map›Paper›PMID 39097072›Full record

ArticleExperimental eye research2024

Reversal of injury-associated retinal ganglion cell gene expression by a phosphodiesterase anchoring disruptor peptide.

Ying Zhu, Ramesh V Nair, Xin Xia, Michael Nahmou, Xueyi Li, Wenjun Yan, Jinliang Li, Bogdan Tanasa, Jeffrey L Goldberg, Michael S Kapiloff

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental eye research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ying ZhuDepartment of Ophthalmology, Byers Eye Institute, Mary M. and Sash A. Spencer Center for Vision Research, Stanford University School of Medicine, Palo Alto, CA, 94034, USA.
Ramesh V NairStanford Center for Genomics and Personalized Medicine, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Xin XiaDepartment of Ophthalmology, Byers Eye Institute, Mary M. and Sash A. Spencer Center for Vision Research, Stanford University School of Medicine, Palo Alto, CA, 94034, USA.
Michael NahmouDepartment of Ophthalmology, Byers Eye Institute, Mary M. and Sash A. Spencer Center for Vision Research, Stanford University School of Medicine, Palo Alto, CA, 94034, USA.
Xueyi LiDepartment of Ophthalmology, Byers Eye Institute, Mary M. and Sash A. Spencer Center for Vision Research, Stanford University School of Medicine, Palo Alto, CA, 94034, USA.
Wenjun YanDepartment of Ophthalmology, Byers Eye Institute, Mary M. and Sash A. Spencer Center for Vision Research, Stanford University School of Medicine, Palo Alto, CA, 94034, USA.
Jinliang LiDepartment of Ophthalmology, Byers Eye Institute, Mary M. and Sash A. Spencer Center for Vision Research, Stanford University School of Medicine, Palo Alto, CA, 94034, USA.
Bogdan TanasaDepartment of Ophthalmology, Byers Eye Institute, Mary M. and Sash A. Spencer Center for Vision Research, Stanford University School of Medicine, Palo Alto, CA, 94034, USA.
Jeffrey L GoldbergDepartment of Ophthalmology, Byers Eye Institute, Mary M. and Sash A. Spencer Center for Vision Research, Stanford University School of Medicine, Palo Alto, CA, 94034, USA.
Michael S KapiloffDepartment of Ophthalmology, Byers Eye Institute, Mary M. and Sash A. Spencer Center for Vision Research, Stanford University School of Medicine, Palo Alto, CA, 94034, USA. Electronic address: kapiloff@stanford.edu.

Funding

Stanford Vision Research CoreP30EY026877 · NEI · STANFORD UNIVERSITY · PI Jeffrey L Goldberg · 2017 to 2026
$8.0M
Gene Expression Regulatory Pathways and Retinal Ganglion Cell NeuroprotectionR01EY032416 · NEI · STANFORD UNIVERSITY · PI GOLDBERG, JEFFREY L, KAPILOFF, MICHAEL SETH · 2021 to 2024
$2.2M
CaMKII: Retinal Ganglion Cell Neuroprotection and Axon RegenerationR01EY036028 · NEI · STANFORD UNIVERSITY · PI Jeffrey L Goldberg, Michael Seth Kapiloff · 2024 to 2026
$1.7M
VRC: The Role of Perinuclear cAMP in Retinal Ganglion Cell Neuroprotection and Optic Nerve RegenerationR01EY031167 · NEI · STANFORD UNIVERSITY · PI KAPILOFF, MICHAEL SETH · 2019 to 2021
$1.0M
NEI NIH HHS P30 EY026877NEI NIH HHS R01 EY031167NEI NIH HHS R01 EY032416NEI NIH HHS R01 EY036028
6 · The paper itself

Abstract

Loss of retinal ganglion cells (RGCs) is central to the pathogenesis of optic neuropathies such as glaucoma. Increased RGC cAMP signaling is neuroprotective. We have shown that displacement of the cAMP-specific phosphodiesterase PDE4D3 from an RGC perinuclear compartment by expression of the modified PDE4D3 N-terminal peptide 4D3(E) increases perinuclear cAMP and protein kinase A activity in cultured neurons and in vivo RGC survival after optic nerve crush (ONC) injury. To explore mechanisms by which PDE4D3 displacement promotes neuroprotection, in this study mice intravitreally injected with an adeno-associated virus to express an mCherry-tagged 4D3(E) peptide were subjected to ONC injury and analyzed by single cell RNA-sequencing (scRNA-seq). 4D3(E)-mCherry expression was associated with an attenuation of injury-induced changes in gene expression, thereby supporting the hypothesis that enhanced perinuclear PKA signaling promotes neuroprotective RGC gene expression.

Indexed as

Mice, Inbred C57BLOptic Nerve InjuriesRetinal Ganglion CellsAnimalsCells, CulturedCell SurvivalCyclic AMP-Dependent Protein KinasesCyclic Nucleotide Phosphodiesterases, Type 4Disease Models, AnimalGene Expression RegulationIntravitreal InjectionsMaleMiceNerve CrushSignal TransductionCyclic AMP-Dependent Protein KinasesCyclic Nucleotide Phosphodiesterases, Type 4cAMPGene expressionNeuroprotectionRetinal ganglion cell

Identifiers

PMID39097072
PMCPMC11330710

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.